Compare Amylx Pharmaceuticals Inc (AMLX) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Tilray Brands Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Tilray Brands Inc trades at $4.81 (market cap $601.34M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 4.2× Tilray Brands Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | TLRY | |
|---|---|---|
Market Cap | $2.53B | $601.34M |
Sector | Health | Health |
52-Week High | $24.19 | $21.00 |
52-Week Low | $7.82 | $3.88 |
Enterprise Value | $2.28B | $768.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
TLRY trades at $4.57, up 2.93% with a bullish technical signal, though recent earnings misses and negative profitability metrics highlight fundamental challenges. The company reported record fiscal 2026 revenue of $915 million but continues to post significant net losses. Analyst sentiment is mixed with 25% buy ratings, while technical indicators show RSI near overbought levels with key support at $4.
Outlook remains cautious due to persistent losses and high valuation multiples, though revenue growth and diversification into beverages offer potential upside. Key risks include execution challenges, cannabis regulatory uncertainty, and competitive pressures in the consumer goods space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
